Optimal Timing of Pavement Preventive Maintenance Treatment Applications

2004 ◽  
Author(s):  
◽  
Author(s):  
Momen R. Mousa ◽  
Mostafa A. Elseifi ◽  
Zhongjie Zhang ◽  
Kevin Gaspard

Preventive maintenance treatments are widely used throughout the United States to extend pavement service life (PSL), and therefore, defer costly rehabilitation activities. However, optimizing the use of these treatments faces several key challenges. First, the benefits resulting from these treatments are not well-defined. Second, there is considerable debate over the optimal timing of these treatments. Third, concerns exist that these treatments may be responsible for moisture damage if the surrounding moisture conditions are not adequately considered before installation. Although significant research has been conducted to address these challenges, few efforts have been directed toward technology transfer and implementation of the research findings. Therefore, the objective of this study was to combine the results of a comprehensive research study addressing these challenges into an enhanced decision-making tool that can be used to select the best maintenance treatment to be applied to an existing asphalt concrete (AC) overlay based on the project conditions. For a given project, this tool will predict the most cost-effective maintenance treatment (crack sealing, chip seal, microsurfacing, or do nothing) to address existing surface distresses without causing moisture damage. The tool will also provide the optimal timing of installation of the recommended treatment. To ensure that the developed tool is practical and simple to use, it was developed using macros in Microsoft Excel. The developed tool is implementation-ready and should be utilized by the relevant Department of Transportation to maximize the benefits from pavement maintenance activities.


2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Sudeep Gupta ◽  
Shona Nag ◽  
Shyam Aggarwal ◽  
Amit Rauthan ◽  
Narayanankutty Warrier

Abstract Epithelial ovarian cancer (EOC) is usually diagnosed late at an advanced stage. Though EOC initially responds to treatment, the recurrence rate is pretty high. The efficacy of different targeted therapies reduces with each recurrence. Hence there is need of effective maintenance therapy in recurrent EOC. Recently, polyADP-ribose polymerase (PARP) inhibitors (PARPi) have been approved both for initial treatment of EOC and as its maintenance treatment. PARPi have also been found to act regardless of BRCA status or homologous recombination (HR) deficiency. Several trials testing PARPi early in maintenance therapy are in progress and their results will shed light on the optimal timing of maintenance therapy that gives the most benefit with least toxicity. Right patient selection for maintenance treatment is also a challenge. Hence, though PARPi are emerging as a promising maintenance treatment in recurrent EOC with prolongation of progression free survival (PFS), results from further trials and overall survival (OS) data from current trials are awaited to fulfill the gaps in understanding the role of this pathway in treatment of EOC. This review discusses the current therapies for EOC, challenges in the treatment of recurrent EOC, recent developments and trials in recurrent EOC maintenance with special focus on PARPi and future perspectives.


2004 ◽  
Vol 62 (5) ◽  
pp. 282-288 ◽  
Author(s):  
Birgitta Rosén ◽  
Göran Olavi ◽  
Dowen Birkhed ◽  
Stig Edvardsson ◽  
Jan Egelberg

1999 ◽  
Vol 26 (4) ◽  
pp. 225-233 ◽  
Author(s):  
Birgitta Rosén ◽  
Gran Olavi ◽  
Anita Badersten ◽  
Anders Rönström ◽  
Göran Söderholm ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document